Vertex reports second positive pivotal Phase III study for HCV protease inhibitor telaprevir
This article was originally published in Scrip
Executive Summary
Vertex has released positive results from the second Phase III study of the investigational hepatitis C protease inhibitor telaprevir, showing that for those patients who responded to the drug early on in treatment, a total of 24 weeks' therapy was just as effective as 48 weeks.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.